Centogene N.V.




Biotechnology & Medical Research

Delayed Nasdaq 21:30:00 14/06/2024 BST 5-day change 1st Jan Change
0.3707 USD -0.48% Intraday chart for Centogene N.V. +1.84% -69.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Upcoming Slew of Economic Data Buoys Exchange-Traded Funds, Equity Futures Pre-Bell Thursday MT
Top Premarket Gainers MT
Centogene N.V. Provides Earnings Guidance for the Year 2024 CI
Centogene N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment MT
Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease CI
Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients CI
Centogene Gets Nasdaq Noncompliance Notice MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics MT
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders CI
Centogene Explores Strategic Alternatives CI
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration CI
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics CI
Centogene N.V. Provides Earnings Guidance for the Full Year 2023 CI
Centogene N.V. Announces Changes to Supervisory Board CI
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone CI
Centogene, Saudi Arabia's Public Investment Fund Form JV MT
Centogene N.V. and Lifera Complete Strategic Joint Venture Transaction CI
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism CI
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering CI
Flemming Ornskov Decides to Step Down from His Role as a Member of the Supervisory Board of Centogene CI
Centogene N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023 CI
Upcoming Payrolls Report Lifts Exchange-Traded Funds, Equity Futures Premarket Friday MT
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients CI
Chart Centogene N.V.
More charts
Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
More about the company
Mean consensus
Number of Analysts
Last Close Price
0.3466 EUR
Average target price
1.378 EUR
Spread / Average Target
  1. Stock Market
  2. Equities
  3. CNTG Stock
  4. News Centogene N.V.
  5. Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.